唑来膦酸联合化疗治疗非小细胞肺癌骨转移的临床效果

Clinical effect of Zoledronic Acid combined with chemotherapy treating bone metastasis of non-small cell lung cancer

目的分析唑来膦酸联合化疗治疗非小细胞肺癌(NSCLC)骨转移的临床效果,以期为临床治疗方案的选取提供参考。方法回顾性分析2018年1月1日~2019年1月1日于我院治疗的82例NSCLC骨转移患者的临床资料,依据治疗方法的不同将其分为两组,将接受常规化疗治疗的39例患者作为对照组,接受化疗、唑来膦酸联合治疗的43例患者作为观察组。观察两组的临床疗效、骨痛评分及不良反应。结果观察组疾病控制率(93.02%)高于对照组(76.92%),差异有统计学意义(P<0.05);治疗前,两组疼痛数字量表(NRS)评分比较,差异无统计学意义(P>0.05);治疗后,两组NRS评分均低于治疗前,观察组NRS评分[(1.42±0.91)分]低于对照组的(2.59±1.27)分,差异有统计学意义(P<0.05);观察组与对照组的胃肠道反应、骨髓抑制、发热发生率比较(23.26%vs.30.77%、20.93%vs.17.95%、11.63%vs.7.69%),差异无统计学意义(P>0.05)。结论唑来膦酸、化疗联合治疗NSCLC骨转移能够改善患者骨痛症状,抑制肿瘤生长及进展,在提升治疗效果外,且未增加不良反应。

Objective To analyze the clinical effect of Zoledronic Acid combined with chemotherapy treating bone metastasis of non-small cell lung cancer(NSCLC),in order to provide reference for the selection of clinical treatment.Methods The clinical data of 82 patients with NSCLC bone metastasis who were treated in our hospital from January 1,2018 to January 1,2019 were analyzed retrospectively.According to the different treatment methods,they were divided into two groups.A total of 39 patients who received conventional chemotherapy were set as the control group and 43 patients who received chemotherapy and Zoledronic Acid as the observation group.The clinical effect,bone pain score and adverse reactions were observed.Results The disease control rate of the observation group(93.02%)was higher than that of the control group(76.92%),the difference was statistically significant(P<0.05).Before treatment,there was no significant difference between the two groups in numeric rating scale(NRS)score(P>0.05).After treatment,the NRS scores of both groups were lower than those before treatment,the NRS score of the observation group([1.42±0.91]points)was lower than that of the control group([2.59±1.27]points),the differences were statistically significant(P<0.05).The incidence rates of gastrointestinal reactions,bone marrow suppression and fever in the observation group and the control group were compared(23.26% vs.30.77%,20.93% vs.17.95%,11.63%vs.7.69%),with no significant difference(P>0.05).Conclusion Zoledronic Acid combined with chemotherapy treating NSCLC bone metastasis can improve the symptoms of bone pain,inhibit the growth and progress of tumor,and improve the therapeutic effect without increasing adverse reactions.